Clinical Trials Logo

Clinical Trial Summary

Hyperosmotic solutions of 1.5% and 3% NaCl are equally effective for brain relaxation and microcirculation during brain surgery. The effect of 1.5% NaCl on postoperative natremia and natriuresis is less pronounced.


Clinical Trial Description

All the patients meeting the study criteria will be randomized into two groups. After standardized induction to general anesthesia all patients will be given the infusion of hyperosmotic NaCl 5 ml/kg/BW during 30 min, group A 1.5% NaCl, group B 3% NaCl. Corticosteroids will be administered as usually. After dura opening the brain relaxation score will be assessed by surgeon (1 = completely relaxed, 2 = satisfactorily relaxed, 3 = firm brain, 4 = bulging brain), and the first measurement of the brain microcirculation provided by use of SDF probe in the area of the healthy brain, and of perifocal oedema. Both sites of investigation will be marked for the second measurement, which will be done after the end of tumor resection. Laboratory examinations: natremia preoperatively, natremia and osmolarity peroperatively 1 hour after NaCl infusion and at the end of surgery. Concentration of natrium will be examined in CSF after dura opening. Anesthesia management will be according to the standardised protocol, the patients will be awaken and extubated after the end of the procedure at the operating theatre. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02537106
Study type Interventional
Source University Hospital Hradec Kralove
Contact
Status Completed
Phase N/A
Start date September 2015
Completion date May 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Completed NCT01951950 - Nicardipine vs Esmolol Craniotomy Emergence Phase 1
Completed NCT01222780 - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase 1
Completed NCT00873184 - Study of Massage Therapy Within a Brain Tumor Setting N/A
Active, not recruiting NCT01115777 - Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Completed NCT00003935 - Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma Phase 1
Completed NCT00724191 - Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
Recruiting NCT04128306 - Brain Areas of Time-To-Contact Perception: an Awake Surgery Study N/A
Recruiting NCT05202899 - Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy Phase 4
Completed NCT00707343 - [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors Phase 1
Completed NCT00850278 - Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors N/A
Completed NCT00528437 - Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors Phase 2
Terminated NCT00107471 - Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma Phase 1/Phase 2
Completed NCT00187174 - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors Phase 1
Completed NCT00135876 - Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Phase 3
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Completed NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Terminated NCT01018290 - Navigated Transcranial Magnetic Stimulation in Tumor Surgery N/A
Completed NCT00003573 - Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Phase 2